Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPTION 2: A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis; With an Extension Phase Evaluation of Immediate Release MS1819 Capsules

NCT04375878 is registered in ClinicalTrials.gov with Entero Therapeutics as lead sponsor.

NCT NCT04375878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04375878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPTION 2: A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis; With an Extension Phase Evaluation of Immediate Release MS1819 Capsules
Lead sponsor
Entero Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 20, 2020
Completion date
April 8, 2021
Enrollment
27 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis (cf), exocrine pancreatic insufficiency (epi)